Entasis Therapeutics Overview

  • Founded

  • 2015

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 55

Employees
  • Latest Deal Type

  • M&A

  • Financing Rounds

  • 9

Entasis Therapeutics General Information

Description

Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).

Contact Information

Website
www.entasistx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Parent Company
Innoviva
Former Stock Listing
ETTX
Primary Office
  • Boston BioHub
  • 35 Gatehouse Drive
  • Waltham, MA 02451
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Entasis Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Entasis Therapeutics‘s full profile, request access.

Request a free trial

Entasis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, developme
Pharmaceuticals
Waltham, MA
55 As of 2022
00000
0000 0000-00-00
000000&0 00000

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 000000000
Jersey City, NJ
00 As of 0000
00000
00000000 00000

000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vo
000000000000000
Dublin, Ireland
0000 As of 0000
00000
00.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Entasis Therapeutics Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Scynexis Formerly VC-backed Jersey City, NJ 00 00000 00000000 00000
0000000 0000000000 Corporation Dublin, Ireland 0000 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
00000000000 Formerly VC-backed Rockville, MD 000 00000 000000000 00000
You’re viewing 5 of 29 competitors. Get the full list »

Entasis Therapeutics Patents

  • 86

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 5

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Entasis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020415391-A1 Managing microbial dysbiosis with temocillin Pending 23-Dec-2019 0000000000
CA-3162777-A1 Managing microbial dysbiosis with temocillin Pending 23-Dec-2019 0000000000
EP-4081214-A1 Managing microbial dysbiosis with temocillin Pending 23-Dec-2019 0000000000
US-20230068309-A1 Managing microbial dysbiosis with temocillin Pending 23-Dec-2019 0000000000
US-11046694-B2 Compounds and methods for treating bacterial infections Active 08-May-2018 C07D471/08
To view Entasis Therapeutics’s complete patent history, request access »

Entasis Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Manoussos Perros Ph.D Founder & Chief Executive Officer & President
Matthew Ronsheim Ph.D President
John Mueller Ph.D Chief Development Officer
Ruben Tommasi Ph.D Chief Scientific Officer
David Altarac Chief Medical Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Entasis Therapeutics Board Members (13)

Name Representing Role Since
0000000 0000000 00 Pivotal bioVenture Partners Board Member 000 0000
You’re viewing 1 of 13 board members. Get the full list »

Entasis Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Entasis Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Entasis Therapeutics‘s full profile, request access.

Request a free trial